Alzamend Neuro, Inc.
$1.11
▼
-1.97%
2026-04-21 05:15:01
www.alzamend.com
NCM: ALZN
Explore Alzamend Neuro, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.26 M
Current Price
$1.11
52W High / Low
$8.22 / $0.84
Stock P/E
—
Book Value
$0.57
Dividend Yield
—
ROCE
-113.32%
ROE
-2.5%
Face Value
—
EPS
$-3.67
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
-0.05
Debt / Equity
—
Current Ratio
1.99
Quick Ratio
6.58
Forward P/E
-0.33
Price / Sales
—
Enterprise Value
$0.55 M
EV / EBITDA
-0.08
EV / Revenue
—
Rating
Strong Buy
Target Price
$25
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Caribou Biosciences, Inc. | $2.29 | — | $212.6 M | — | -90.82% | -78.97% | $3.54 / $0.71 | $1.28 |
| 2. | Genelux Corporation | $2.65 | — | $125.01 M | — | -259.44% | -1.7% | $8.54 / $2.25 | $0.31 |
| 3. | CAMP4 THERAPEUTICS CORPORATION | $4.51 | — | $233.12 M | — | -50.89% | -1.45% | $7.75 / $1.3 | $0.92 |
| 4. | LB Pharmaceuticals Inc | $31.67 | — | $875.16 M | — | -9.95% | -15.7% | $30.72 / $13.36 | $11.91 |
| 5. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 6. | TuHURA Biosciences, Inc. | $2.83 | — | $179.93 M | 0% | -120.19% | -1.69% | $4.44 / $0.41 | $0.35 |
| 7. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.2 M | -1 M | -2.7 M | -1.14 M | -1.04 M | — |
| Net Profit | -2.2 M | -1 M | -2.7 M | -1.14 M | -1.04 M | — |
| EPS in Rs | -0.58 | -0.26 | -0.71 | -0.3 | -0.27 | -3.61 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -4.5 M | -9.94 M | -14.87 M | -12.32 M |
| Net Profit | -4.51 M | -9.95 M | -14.88 M | -12.36 M |
| EPS in Rs | -1.19 | -2.61 | -3.91 | -3.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.6 M | 0.63 M | 5.92 M | 14.52 M |
| Total Liabilities | 0.63 M | 3.23 M | 2.87 M | 1.16 M |
| Equity | 3.97 M | -2.59 M | 3.05 M | 13.35 M |
| Current Assets | 4.18 M | 0.46 M | 5.84 M | 14.41 M |
| Current Liabilities | 0.63 M | 3.23 M | 2.87 M | 1.16 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.57 M | -8.27 M | -8.92 M | -6.61 M |
| Investing CF | -0.3 M | -0.15 M | 0 M | -0.11 M |
| Financing CF | 10.44 M | 3.65 M | 0 M | 18.85 M |
| Free CF | -6.87 M | -8.42 M | -8.92 M | -6.72 M |
| Capex | -0.3 M | -0.15 M | — | -0.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 33.14% | -20.35% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-05-12 | 1:0.111111 |
| 2024-07-16 | 1:0.1 |
| 2023-10-31 | 1:0.0666667 |